|Brand names||Nipolept, Lodopin, Zoleptil|
Zotepine is an atypical antipsychotic that has been discontinued in Germany, the U.K., and was never approved for clinical use in Australia or the U.S.A., although it is still used in Japan and Portugal. According to a recent review article it is no more effective than other antipsychotics (both typical and atypical), although it is more prone than most other atypicals to cause movement disorders, weight gain and sedation. Zotepine is believed to be more prone than clozapine to elevate prolactin levels, although this is based on just one clinical trial. It also increases the production of uric acid, hence potentially worsening gout.
It, compared to most other antipsychotics, is a stronger antagonist at the 5-HT6 and 5-HT7 receptors, meaning there is the theoretical potential for it possess unique effectiveness in alleviate the cognitive symptoms of schizophrenia, although this is yet to be confirmed or discredited by clinical trial data. It is also a noradrenaline reuptake inhibitor, similarly to quetiapine's active metabolite, norquetiapine.
- NCBI Bookshelf provides free book resources on this topic.
- PubMed provides review articles from the past five years (limit to free review articles or to systematic reviews)
- The TRIP database provides clinical publications about evidence-based medicine.
- ↑ 1.0 1.1 Brayfield, A, ed. (16 August 2013). "Zotepine". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 5 September 2014.
- ↑ Leucht, S; Cipriani, A; Spineli, L; Mavridis, D; Orey, D; Richter, F; Samara, M; Barbui, C; Engel, RR; Geddes, JR; Kissling, W; Stapf, MP; Lässig, B; Salanti, G; Davis, JM (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.". Lancet 382 (9896): 951–62. PMID 23810019. doi:10.1016/S0140-6736(13)60733-3.
- ↑ Subramanian, S; Rummel-Kluge, C; Hunger, H; Schmid, F; Schwarz, S; Kissling, W; Leucht, S; Komossa, K (October 2010). "Zotepine versus other atypical antipsychotics for schizophrenia.". The Cochrane Database of Systematic Reviews (10): CD006628. PMID 20927748. doi:10.1002/14651858.CD006628.pub3.
- ↑ 4.0 4.1 Green, B (February 2009). "Zotepine: a clinical review.". Expert Opinion on Drug Metabolism & Toxicology 5 (2): 181–6. PMID 19199377. doi:10.1517/17425250802670482.